Library / Ipamorelin
Some human studies
Ipamorelin
Growth hormone secretagogue (ghrelin receptor agonist) · Growth hormone
What it is
A small five-amino-acid peptide that prompts the pituitary gland to release growth hormone.
What research covers
Early studies found it raised growth hormone with less effect on cortisol and prolactin than older compounds. It reached mid-stage human trials for gut recovery after surgery but was not approved.
Reported side effects
- Injection-site reactions
- Flushing or a brief head rush
- Headache
- Increased hunger in some people
Not suitable for, or talk to a doctor first
- Active cancer
- Pregnancy
- Diabetes without medical supervision
Good to know
- Often discussed alongside GHRH analogues such as CJC-1295.
Legal status
| Australia | Not an approved medicine in Australia. Peptides like this are generally prescription-only (Schedule 4) and need a prescription to import. Check current rules with the TGA. |
|---|---|
| United States | Not FDA-approved. |
| Sport | Prohibited by the World Anti-Doping Agency (WADA) at all times. |
Rules change. Check with the TGA (Australia), your local regulator, or WADA for sport.
Key references
- Raun et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
General information, not advice. Talk to a qualified healthcare professional before starting, changing or stopping anything.